Notice2023-18088
Notice Pursuant to The National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 23, 2023
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 162 (Wednesday, August 23, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 162 (Wednesday, August 23, 2023)]
[Notices]
[Page 57479]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-18088]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to The National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on June 23, 2023, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development &
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery
Consortium, Inc.'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Becton, Dickinson and Company, Franklin Lakes, NJ, has
been added as a party to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on December 21,
2022. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on January 25, 2023 (88 FR 4850).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2023-18088 Filed 8-22-23; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on August 23, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.